| abstract |
Disclosed are methods useful for diagnosis, prognosis, treatment, and management of acute myeloid leukemia. One method involves predicting the survival of patients with acute myeloid leukemia, said method comprising cytogenetic abnormalities and FLT3, NPM1, DNMT3A, NRAS, CEBPA, TET2, WTI, IDH1, IDH2, KIT, Analyzing a gene sample isolated from a patient for the presence of at least one of RUNX1, MLL-PTD, ASXL1, PHF6, KRAS, PTEN, p53, HRAS, and EZH2 mutations. |